



# Pharmaids Pharmaceuticals Limited

Date: 12.11.2020

To

Department of Corporate Service  
BSE Limited  
PJ Towers, Dalal Street,  
Fort Mumbai-400001.  
Dear Sir / Madam,

**BSE Script Code: 524572**

**Subject: Outcome of Board Meeting – November 12, 2020**

The Board of Directors of the Company at their meeting held today i.e. Thursday, November 12, 2020 has inter alia, considered and approved the following business:

- 1) Approval of unaudited Financial Results for the Quarter and Half Year ended 30<sup>th</sup> September, 2020 Pursuant to regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, The Board of Directors have approved the unaudited Financial Results of the company for the Quarter and Half Year ended Sep 30, 2020, which are enclosed herewith along with the Limited Review Reports issued by M/s. PPKG & Co, the Statutory Auditors of the Company.

The financial results are also available on the website of the Company at [www.pharmaids.com](http://www.pharmaids.com) and also on the website of BSE Ltd. Viz. [www.bseindia.com](http://www.bseindia.com).

- 2) The Board has deliberated the fund raising plans and authorised Mr. Sadhanala Viswa Prasad, Executive Director to explore the various options for raising the funds to strength the working capital and meeting general corporate requirements of the company.

The meeting of the Board of Directors of the Company Commenced at 1.30 PM and concluded at 3.00 PM.


Please take note of the same on your record.

Thanking You,

Yours faithfully

For Pharmaids Pharmaceuticals Limited

*Padma*  
S. Padmaja Kalyani  
Director (DIN: 03096445)





# Pharmaids Pharmaceuticals Limited

## Pharmaids Pharmaceuticals Limited

Statement of Unaudited Financial Results for the quarter ended 30th Sep 2020

Particulars	Rupees in lakhs					
	Quarter ended			Six month ended		Year ended
	30/09/2020	30/06/2020	30/09/2019	30/09/2020	30/09/2019	31/03/2020
	Unaudited (Reviewed)	Audited				
Income						
Revenue from Operations	325.58	0.00	-1.20	325.58	0.00	0.00
Other Income	0.00	2.63	0.00	2.63	0.00	0.00
<b>Total Income</b>	<b>325.58</b>	<b>2.63</b>	<b>-1.20</b>	<b>328.21</b>	<b>0.00</b>	<b>0.00</b>
Expenses						
Cost of Material Consumed	0.00	0.00	0.00	0.00	0.00	0.00
Purchase of Stock in Trade	382.61	0.00	0.00	382.61	0.00	0.00
Changes in Inventory of Finished Goods, Work in Progress and Stock in Trade	-70.29	0.00	0.00	-70.29	0.00	0.00
Employee benefit expenses	0.60	0.30	0.55	0.90	1.51	2.28
Finance Cost	0.00	0.00	-0.01	0.00	0.08	0.08
Depreciation and amortisation expense	1.11	1.11	1.15	2.22	1.86	3.88
Other expenses	6.70	0.88	4.92	7.58	11.17	31.27
<b>Total expenses</b>	<b>320.72</b>	<b>2.29</b>	<b>6.60</b>	<b>323.01</b>	<b>14.61</b>	<b>37.52</b>
Profit/ (loss) before exceptional items and tax	4.86	0.34	-7.80	5.20	-14.61	-37.52
Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
<b>Profit/ (loss) before tax</b>	<b>4.86</b>	<b>0.34</b>	<b>-7.80</b>	<b>5.20</b>	<b>-14.61</b>	<b>-37.52</b>
Tax expenses:						0.00
(1) Current Tax	1.13	0.00	0.00	1.13	0.00	0.00
(2) Deferred Tax	0.00	0.00	0.00	0.00	0.00	-40.87
Profit/ (loss) for the period from continuing operations	3.73	0.34	-7.80	4.07	-14.61	3.35
Profit/ (loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
Profit/ (loss) from discounting operations (after tax)	0.00	0.00	0.00	0.00	0.00	0.00
<b>Profit/ (loss) for the period</b>	<b>3.73</b>	<b>0.34</b>	<b>-7.80</b>	<b>4.07</b>	<b>-14.61</b>	<b>3.35</b>
Other comprehensive income	0.00	0.00	0.00	0.00	0.00	0.00
Total comprehensive income for the period	0.00	0.00	0.00	0.00	0.00	0.00
(Profit/ loss + other comprehensive income)	0.00	0.00	0.00	0.00	0.00	0.00
Earnings per equity share (for continuing operations)						
a) Basic	0.04	0.00	-0.08	0.04	-0.14	0.03
b) Diluted	0.04	0.00	-0.08	0.04	-0.14	0.03
Earnings per equity share (for discontinued operations)						
a) Basic	0.00	0.00	0.00	0.00	0.00	0.00
b) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
Earnings per equity share (for discontinued & continuing operations)						
a) Basic	0.04	0.00	-0.08	0.04	-0.14	0.03
b) Diluted	0.04	0.00	-0.08	0.04	-0.14	0.03

**NOTES:** 1. The above results were approved at the meeting of the Board of Directors held on November 12, 2020. 2. The Company operates in a single segment 3. As required under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, the Limited Review by the Statutory Auditors has been completed and the Unmodified Report forwarded to BSE Ltd. The said Report does not have any impact on the above results and Notes which needs explanation. 4. As per NCLT order dated 27-09-2019, Pharmaids Pharmaceuticals Limited undergone amalgamation with Emergent Bio Naturals Limited w.e.f 01-04-2018 as explained in Para 5 of the Auditor's Report. 5. The previous's quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / period. 6. During this pandemic, business operations and financial position has revealed that there has been no significant impact on company's financial results as at 30th Sep 2020. However, the impact assessment of COVID-19 will be a continuing process given the uncertainties associated with its nature and duration and accordingly the impact may be different from that estimated as at the date of approval of these financial results. The Company will continue to monitor such impact to future economic conditions.

For Pharmaids Pharmaceuticals Limited

Place: Hyderabad  
Date: 12/11/2020

S. Padmaja Kalyani

Director (DIN: 03096445)



Office Address : 503, Amrutha Estate, Himayath Nagar, Hyderabad - 500029. Ph: 040 - 40122151

CIN No: L52520TG1989LC009679, GSTIN No : 36AABCP4657N2ZW

Email : pharmaids125@gmail.com , Web : www.pharmaids.com



# Pharmaids Pharmaceuticals Limited

Pharmaids Pharmaceuticals Limited

Balance Sheet as at 30th September, 2020

Rs. (In Lakhs)

	Particulars	Note No.	Figures as at the end of 30.09.2020	Figures as at the end of 31.03.2020
	1	2	3	4
<b>1 ASSETS</b>				
	<b>Non-current assets</b>			
	(a) Property, Plant and Equipment		6.24	8.31
	(b) Capital work-in-progress		45.00	45.00
	(c) Investment Property		-	-
	(d) Goodwill		-	-
	(e) Other Intangible assets		-	-
	(f) Intangible assets under development		-	-
	(g) Biological Assets other than bearer plants		-	-
	(h) Financial Assets			
	(i) Investments		-	-
	(ii) Trade receivables		75.85	75.85
	(iii) Loans		632.33	643.35
	(iv) Others (to be specified)		-	-
	(i) Deferred tax assets (net)		34.58	34.58
	(j) Other non-current assets		-	-
<b>2 Current assets</b>				
	(a) Inventories		70.29	-
	(b) Financial Assets			
	(i) Investments		-	-
	(ii) Trade receivables		89.61	-
	(iii) Cash and cash equivalents		19.75	2.18
	(iv) Bank balances other than (iii) above		-	-
	(v) Loans and Advances		36.55	36.55
	(vi) Others (to be specified)		-	-
	(c) Current Tax Assets (Net)		-	-
	(d) Other current assets		9.94	-
	<b>Total Assets</b>		<b>1,020.13</b>	<b>845.82</b>
	<b>EQUITY AND LIABILITIES Equity</b>			
	(a) Equity Share capital		1,026.88	1,026.88
	(b) Other Equity		(179.50)	(183.57)
	<b>LIABILITIES</b>			
<b>1 Non-current liabilities</b>				
	(a) Financial Liabilities			
	(i) Borrowings		-	-
	(ii) Trade payables		-	-
	(iii) Other financial liabilities (other than those specified in (b) Provisions		-	-
	(c) Deferred tax liabilities (Net)		-	-
	(d) Other non-current liabilities		-	-
<b>2 Current liabilities</b>				
	(a) Financial Liabilities			
	(i) Borrowings		-	-
	(ii) Trade payables		170.40	1.07
	(iii) Other financial liabilities (other than those specified in (b) Other current liabilities		1.22	1.44
	(c) Provisions		1.13	-
	(d) Current Tax Liabilities (Net)		-	-
	<b>Total Equity and Liabilities</b>		<b>1,020.13</b>	<b>845.82</b>

For Pharmaids Pharmaceuticals Limited

Place: Hyderabad

S. Padmaja Kalyani

Date: 12/11/2020

Director (DIN: 03096449)

Office Address : 503, Amrutha Estate, Himayath Nagar, Hyderabad - 500029. Ph: 040 - 40122151

CIN No: L52520TG1989LC009679, GSTIN No : 36AABCP4657N2ZW

Email : pharmaids125@gmail.com , Web : www.pharmaids.com





# Pharmaids Pharmaceuticals Limited

Pharmaids Pharmaceuticals Limited

## Cash Flow Statement

Rs. (In Lakhs)

	Particulars	Figures as at the end of 30.09.2020 (Unaudited)	Figures as at the end of 30.09.2019 (Unaudited)
<b>A</b>	<b>CASHFLOW FROM OPERATING ACTIVITIES:</b>		
	Net Profit before Tax	5.20	(14.61)
	<b>Adjustment for:</b>		
	Depreciation and Amortization	2.22	1.86
	Interest Charged	-	0.08
	Interest Income		
	Dividend Income/Gain on sale of Investments		
	Provision / write off for doubtful trade receivables		
	Deferred Tax		
	<b>Operating Profit before change in working capital</b>	<b>7.42</b>	<b>(12.68)</b>
	<b>Working capital changes:</b>		
	Changes in Inventories	(70.29)	
	Changes in Trade Receivables	(89.61)	0.00
	Change in Short term loans and advances	-	(9.70)
	Changes in Trade payables	169.33	8.19
	Changes in Other liabilities	(0.22)	-
	Changes in Provisions		
	Changes in Other Current Assets	(9.94)	
	<b>Cash generated from Operations</b>	<b>6.70</b>	<b>(14.18)</b>
	Direct tax paid (Net of Refunds)	-	-
	<b>Net Cash inflow from Operating Activities (A)</b>	<b>6.70</b>	<b>(14.18)</b>
<b>B</b>	<b>CASH FLOW FROM INVESTING ACTIVITIES:</b>		
	Proceeds from Sale Asset		
	Government assistance		
	Interest received		
	Dividend Income /Gain on Sale of Investments received		
	Purchase of property, plant & equipments, intangible assets and Capital Advance	(0.15)	-
	Intangible assets under development		
	Long term loans and Advances (Given)/Repaid	11.01	9.52
	<b>Net Cash inflow from Investing Activities (B)</b>	<b>10.86</b>	<b>9.52</b>
<b>C</b>	<b>CASH FLOW FROM FINANCING ACTIVITIES:</b>		
	Proceeds from borrowings	-	0.00
	Net increase/ (decrease) in working capital demand loans		
	Payment of lease liabilities		
	Increase in Restricted Bank Balances other than Cash & Cash Equivalents		
	Dividends paid (including distribution tax)		
	Interest and other finance costs (including borrowing cost capitalised)	-	(0.08)
	<b>Net Cash inflow from Financing Activities (C)</b>	<b>-</b>	<b>(0.08)</b>
<b>I</b>	<b>Net (decrease)/increase in cash and cash equivalents (A+B+C)</b>	<b>17.56</b>	<b>(4.74)</b>
<b>II</b>	<b>a) Cash and Cash Equivalents at the beginning of the year</b>	<b>2.19</b>	<b>10.88</b>
	<b>b) Effect of Exchange difference on restatement of foreign currency cash and cash equivalents</b>		
	<b>c) Effect of Fairvalue change of investment held for Trading</b>		
<b>III</b>	<b>Cash and Cash Equivalents at the end of the year/period (I+II)</b>	<b>19.75</b>	<b>6.14</b>
<b>IV</b>	<b>Cash and Cash Equivalents at the end of the year/period</b>		
	Balances with Banks	19.53	5.94
	Cash on Hand	0.22	0.20
	<b>Total Cash and Cash Equivalents</b>	<b>19.75</b>	<b>6.14</b>

For Pharmaids Pharmaceuticals Limited

5, Padmaja Kalyan

Director (DIN:03096445)


Place: Hyderabad

Date: 12/11/2020

Office Address : 503, Amrutha Estate, Himayath Nagar, Hyderabad - 500029. Ph: 040 - 40122181 \*

CIN No: L52520TG1989LC009679, GSTIN No : 36AABCP4657N2ZW

Email : pharmaids125@gmail.com , Web : www.pharmaids.com



**INDEPENDENT AUDITOR'S REVIEW REPORT ON  
REVIEW OF INTERIM FINANCIAL RESULTS**

To

The Board of Directors,  
Pharmaids Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited Financial Results of **PHARMAIDS PHARMACEUTICALS LIMITED** ("the Company") for the Quarter and Six months Ended 30<sup>th</sup> September, 2020 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed necessary procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



The Scheme of Amalgamation of Emergent Bio Naturals Limited (EBNL) with Pharmaids Pharmaceuticals Limited was approved by the National Company Law Tribunal vide its order dated 27th September, 2019. The certified copy of the NCLT order was filed with Registered of Companies on 12th October, 2019 consequently the Scheme became operative, and effective date is 1st April, 2018 (Appointed Date). The Company has accounted the Amalgamation as per Appendix C of IND AS 103 Business Combination, the financial information in respect of prior periods has been restated as if the business combination had occurred on April 1st, 2018.


Based on our review conducted as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The Previously issued financial information of the Company for the quarter ended 30<sup>th</sup> September, 2019 included in the Statement, have been restated to give effect to the Scheme of Amalgamation ("the Scheme") of Pharmaids Pharmaceuticals Limited (PPL) with Emergent Bio Naturals Limited, as explained in Para 5 to the Report.

The adjustments made to the previously issued financial information to give effect to the Scheme have been reviewed by us. Our report is not modified in respect of this matter.

Place: Hyderabad  
Date: 12th November, 2020  
UDIN: 20205140AAAJC3249

For PPKG & CO  
Chartered Accountants  
FRN No. 009655S

  
GIRDHARI LAL TOSHNIWAL  
(Partner)  
M. No. 205140

